Trial of three drugs plus temodar
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Combination of Repurposed Drugs plus Temodar |
| FDA Approval | Varies (individual drugs have separate FDA approvals for other conditions) |
| Used for | Investigational use in glioblastoma |
| Clinical Trial Phase | Phase 1 and Phase 2 trials |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Varies based on the combination; potential for increased chemotherapy toxicity |
| OS without | Standard treatment: median survival of 16.1 months |
| OS with | Varies; one combination showed median survival of 20 months, another study reported median survival up to 29.6 months with high-dose Valproic Acid |
| PFS without | Not specified |
| PFS with | Study-specific; one phase 2 trial reported no significant difference in PFS with the addition of celecoxib |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Early clinical trials exploring combinations of repurposed drugs with Temodar for glioblastoma treatment have yielded mixed results. Some combinations have shown potential for improving outcomes, while others have not demonstrated significant benefits over standard treatment. The CUSP9 protocol introduces a conceptually new approach by targeting multiple growth pathways simultaneously with a cocktail of repurposed drugs plus metronomic Temodar, highlighting the importance of simultaneous pathway inhibition for treatment efficacy.
From Ben Williams Book: Not specified
Loading comments...
